Bjørn Tore Gjertsens forskningsgruppe
Blood, 15 March 2007, Vol. 109, No. 6, pp. 2589-2596.
Reikvam H, Kittang AO, Melve G, Mosevoll KA, Bentsen PT, Ersvær E, Gjertsen BT, Bruserud O.
Targeted Anti-Leukemic Therapy as Disease-Stabilizing Treatment for Leukemia Relapse after Allogeneic Stem Cell Transplantation: Will It Be Possible To Combine These Strategies with Retransplantation or Donor Lymphocyte Infusions?
Curr Cancer Drug Targets. 2012 Aug 2.
Oveland E, Wergeland L, Hovland R, Lorens JB, Gjertsen BT, Fladmark KE.
Ectopic expression of Flt3 kinase inhibits proliferation and promotes cell death in different human cancer cell lines.
Cell Biol Toxicol. 2012 Aug;28(4):201-12.
Mdm2 controls CREB-dependent transactivation and initiation of adipocyte differentiation.
Cell Death Differ. 2012 Aug;19(8):1381-9.
Gavasso S, Gjertsen B, Anderssen E, Myhr K, Vedeler C.
Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis.
Mult Scler. 2012 Aug;18(8):1116-24.
Hjelle SM, Sulen A, Oye OK, Jørgensen K, McCormack E, Hollund BE, Gjertsen BT.
Leukocyte p53 protein biosignature through standard-aligned two-dimensional immunoblotting.
J Proteomics. 2012 Jul 26.
Tsykunova G, Reikvam H, Ahmed AB, Nepstad I, Gjertsen BT, Bruserud Ø.
Targeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?
Expert Opin Investig Drugs. 2012 May;21(5):587-603.
Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia.
Leukemia. 2012 May;26(5):910-7.
Fredly H, Reikvam H, Gjertsen BT, Bruserud O.
Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment.
Am J Hematol. 2012 Apr;87(4):368-76.
Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia.
Oncogene. 2012 Mar 22;31(12):1533-45.
Reikvam H, Hatfield KJ, Ersvaer E, Hovland R, Skavland J, Gjertsen BT, Petersen K, Bruserud O.
Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status--consequences and potentials for pharmacological intervention.
Br J Haematol. 2012 Feb;156(4):468-80.
Fredly H, Ersvær E, Gjertsen BT, Bruserud O.
Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis.
Oncol Rep. 2011 Jun;25(6):1549-56.
Stratification of pediatric acute myeloid leukemia through cancer cell gene-expression profiling.
Expert Rev Anticancer Ther. 2011 Mar;11(3):355-7.
Skavland J, Jørgensen KM, Hadziavdic K, Hovland R, Jonassen I, Bruserud Ø, Gjertsen BT
Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia
Blood Cancer Journal (2011) 1, e4; doi:10.1038/bcj.2011.2
McCormack E, Skavland J, Mujic M, Bruserud Ø, Gjertsen BT.
Lentinan: hematopoietic, immunological, and efficacy studies in a syngeneic model of acute myeloid leukemia.
Nutr. Cancer. 2010 Jul;62(5):574-83
Ersvaer E, Liseth K, Skavland J, Gjertsen BT, Bruserud Ø.
Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells.
BMC Immunol. 2010 Jul 9;11:38
Hjelle SM, Forthun RB, Haaland I, Reikvam H, Sjøholt G, Bruserud Ø, Gjertsen BT.
Clinical proteomics of myeloid leukemia.
Genome Med. 2010 Jun 29;2(6):41
Erikstein BS, Hagland HR, Nikolaisen J, Kulawiec M, Singh KK, Gjertsen BT, Tronstad KJ.
Cellular stress induced by resazurin leads to autophagy and cell death via production of reactive oxygen species and mitochondrial impairment.
J Cell Biochem. 2010 Jun 21.
Semaeva E, Tenstad O, Skavland J, Enger M, Iversen PO, Gjertsen BT, Wiig H.
Access to the spleen microenvironment through lymph shows local cytokine production, increased cell flux, and altered signaling of immune cells during lipopolysaccharide-induced acute inflammation.
J Immunol 2010 Apr 15;184(8):4547-56.
Untangling the intracellular signalling network in cancer - a strategy for data integration in acute myeloid leukaemia.
J. Proteomics 2011 Mar 1;74(3):269-81. Epub 2010 Nov 12.
Erikstein BS, McCormack E, Tronstad KJ, Schwede F, Berge R, Gjertsen BT.
Protein kinase A activators and the pan-PPAR agonist tetradecylthioacetic acid elicit synergistic anti-leukaemic effects in AML through CREB.
Leuk. Res. 2010 Jan; 34(1):77-84.
Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival.
Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1124-9.
Christoffersen T, Guren TK, Spindler KL, Dahl O, Lønning PE, Gjertsen BT.
Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues.
Eur J Pharmacol. 2009 Dec 25;625(1-3):6-22.
Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death phenotypes involving modulation of c-FLIPL, Mcl-1, procaspase-8 and mitochondrial function in acute myeloid leukemia cell lines.
Mol Cancer 2009 Nov 13;8:101.
Lukandu OM, Bredholt T, Neppelberg E, Gjertsen BT, Johannessen AC, Vintermyr OK, Costea DE.
Early loss of mitochondrial inner transmembrane potential in khat-induced cell death of primary normal human oral cells.
Toxicology. 2009 Sep 19;263(2-3):108-16.
[Is high hemoglobin level dangerous?]
Tidsskr Nor Laegeforen. 2009 Sep 24;129(18):1881-2.
Reikvam H, Olsnes AM, Gjertsen BT, Ersvar E, Bruserud Ø.
Nuclear factor-kappaB signaling: a contributor in leukemogenesis and a target for pharmacological intervention in human acute myelogenous leukemia.
Crit Rev Oncog. 2009;15(1):1-36
Increased plasma colloid osmotic pressure facilitates the uptake of therapeutic macromolecules in a xenograft model.
Neoplasia 2009 Aug;11(8):812-22
The protein kinase C agonist PEP005 increases NF-kappaB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells.
Br J Haematol. 2009 Jun;145(6):761-74.
Stapnes C, Gjertsen BT, Reikvam H, Bruserud Ø.
Targeted therapy in acute myeloid leukaemia: current status and future directions.
Expert Opin Investig Drugs. 2009 Apr;18(4):433-55
Oyan AM, Anensen N, Hellem Bo T, Stordrange L, Jonassen I, Bruserud O, Kalland KH, Gjertsen BT.
Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia.
BMC Cancer. 2009 Mar 5;9(1):77. [Epub ahead of print]
Oveland E, Gjertsen BT, Wergeland L, Selheim F, Fladmark KE, Hovland R.
Ligand-induced Flt3-downregulation modulates cell death associated proteins and enhances chemosensitivity to idarubicin in THP-1 acute myeloid leukemia cells.
Leuk Res. 2009 Feb;33(2):276-87. Epub 2008 Aug 8.
Hatfield K, Øyan AM, Ersvaer E, Kalland KH, Lassalle P, Gjertsen BT, Bruserud Ø.
Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators.
Br J Haematol. 2009 Jan;144(1):53-68. Epub 2008 Oct 30.
Bruserud Ø, Ersvaer E, Olsnes A, Gjertsen BT.
Anticancer immunotherapy in combination with proapoptotic therapy.
Curr Cancer Drug Targets. 2008 Dec;8(8):666-75. Review.
Ryningen A, Stapnes C, Lassalle P, Corbascio M, Gjertsen BT, Bruserud O.
A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid.
Leuk Res. 2008 Nov 11. [Epub ahead of print]
Ryningen A, Stapnes C, Paulsen K, Lassalle P, Gjertsen BT, Bruserud O.
In vivo biological effects of ATRA in the treatment of AML.
Expert Opin Investig Drugs. 2008 Nov;17(11):1623-33.
McCormack E, Bruserud O, Gjertsen BT.
Review: genetic models of acute myeloid leukaemia.
Oncogene. 2008 Jun 19;27(27):3765-79. Epub 2008 Feb 11. Review.
Erythropoietin a safe bet in haemorrhagic shock?
Acta Anaesthesiol Scand. 2008 May;52(5):585-6. No abstract available.
Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death.
Blood. 2008 Mar 1;111(5):2866-77. Epub 2008 Jan 8.
Khat induces G1-phase arrest and increased expression of stress-sensitive p53 and p16 proteins in normal human oral keratinocytes and fibroblasts.
Eur J Oral Sci. 2008 Feb;116(1):23-30.
Hatfield KJ, Hovland R, Øyan AM, Kalland KH, Ryningen A, Gjertsen BT, Bruserud Ø.
Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic
angiopoietin-2 levels.
Leukemia. 2008 Feb;22(2):287-93. Epub 2007 Oct 18.
Bruserud Ø, Stapnes C, Ersvaer E, Gjertsen BT, Ryningen A.
Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell.
Curr Pharm Biotechnol. 2007 Dec;8(6):388-400. Review.
Gjertsen BT, Bredholt T, Anensen N, Vintermyr OK.
Bcl-2 antisense in the treatment of human malignancies: a delusion in targeted therapy.
Curr Pharm Biotechnol. 2007 Dec;8(6):373-81. Review.
Bruserud Ø, Stapnes C, Ersvaer E, Gjertsen BT, Ryningen A.
Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell.
Curr Pharm Biotechnol. 2007 Dec;8(6):388-400. Review.
Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors.
Int J Oncol. 2007 Dec;31(6):1529-38.
Ersvaer E, Zhang JY, McCormack E, Olsnes A, Anensen N, Tan EM, Gjertsen BT, Bruserud O.
Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients.
Eur J Haematol. 2007 Sep;79(3):210-25. Epub 2007 Jul 26.
Hagland H, Nikolaisen J, Hodneland LI, Gjertsen BT, Bruserud Ø, Tronstad KJ.
Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling.
Expert Opin Ther Targets. 2007 Aug;11(8):1055-69. Review.
Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization.
Anal Biochem. 2007 Jul 1;366(1):46-58. Epub 2007 Mar 18.
Ersvaer E, Hampson P, Hatfield K, Ulvestad E, Wendelbo Ø, Lord JM, Gjertsen BT, Bruserud Ø.
T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-gamma that can be further increased by a novel protein kinase C
agonist PEP005.
Cancer Immunol Immunother. 2007 Jun;56(6):913-25. Epub 2006 Nov 8.
Ersvaer E, Hampson P, Wendelbo Ø, Lord JM, Gjertsen BT, Bruserud Ø.
Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex.
Hematology. 2007 Jun;12(3):199-207.
Wergeland L, Sjøholt G, Haaland I, Hovland R, Bruserud Ø, Gjertsen BT.
Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells.
Mol Cancer. 2007 May 11;6:33.
Anensen N, Øyan AM, Huseby S, Kalland KH, Bruserud Ø, Gjertsen BT.
Early gene expression of acute myeloid leukemia in response to chemotherapy.
Expert Rev Anticancer Ther. 2007 May;7(5):741-51. Review.
McCormack E, Micklem DR, Pindard LE, Silden E, Gallant P, Belenkov A, Lorens JB, Gjertsen BT.
In vivo optical imaging of acute myeloid leukemia by green fluorescent protein: time-domain autofluorescence decoupling, fluorophore quantification, and localization.
Mol Imaging. 2007 May-Jun;6(3):193-204.
Huang TS, Myklebust LM, Kjarland E, Gjertsen BT, Pendino F, Bruserud Ø, Døskeland SO, Lillehaug JR.
LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro.
Irish JM, Anensen N, Hovland R, Skavland J, Børresen-Dale AL, Bruserud O, Nolan GP, Gjertsen BT.
Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53.
Blood. 2007 Mar 15;109(6):2589-96. Epub 2006 Nov 14.
Stapnes C, Døskeland AP, Hatfield K, Ersvaer E, Ryningen A, Lorens JB, Gjertsen BT, Bruserud O.
The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells.
Br J Haematol. 2007 Mar;136(6):814-28.
Bruserud Ø, Ryningen A, Olsnes AM, Stordrange L, Øyan AM, Kalland KH, Gjertsen BT.
Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells.
Haematologica. 2007 Mar;92(3):332-41.
Ersvaer E, Skavland J, Ulvestad E, Gjertsen BT, Bruserud Ø.
Effects of interferon gamma on native human acute myelogenous leukaemia cells.
Cancer Immunol Immunother. 2007 Jan;56(1):13-24. Epub 2006 Apr 13.
Ryningen A, Ersvaer E, Øyan AM, Kalland KH, Vintermyr OK, Gjertsen BT, Bruserud Ø.
Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2:Bax ratio and low levels of heat shock protein 70 and
90.
Leuk Res. 2006 Dec;30(12):1531-40. Epub 2006 Apr 5.
Van Belle W, Sjøholt G, Anensen N, Høgda KA, Gjertsen BT.
Adaptive contrast enhancement of two-dimensional electrophoretic protein gel images facilitates visualization, orientation and alignment.
Electrophoresis. 2006 Oct;27(20):4086-95.
Krakstad C, Herfindal L, Gjertsen BT, Bøe R, Vintermyr OK, Fladmark KE, Døskeland SO.
CaM-kinaseII-dependent commitment to microcystin-induced apoptosis is coupled to cell budding, but not to shrinkage or chromatin hypercondensation.
Cell Death Differ. 2006 Jul;13(7):1191-202. Epub 2005 Nov 25.
Anensen N, Oyan AM, Bourdon JC, Kalland KH, Bruserud O, Gjertsen BT.
A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia.
Clin Cancer Res. 2006 Jul 1;12(13):3985-92.
Anensen N, Haaland I, D'Santos C, Van Belle W, Gjertsen BT.
Proteomics of p53 in diagnostics and therapy of acute myeloid leukemia.
Curr Pharm Biotechnol. 2006 Jun;7(3):199-207. Review.
Oveland E, Fladmark KE, Wergeland L, Gjertsen BT, Hovland R.
Proteomics approaches to elucidate oncogenic tyrosine kinase signaling in myeloid malignancies.
Curr Pharm Biotechnol. 2006 Jun;7(3):185-98. Review.
Sjøholt G, Bedringaas SL, Døskeland AP, Gjertsen BT.
Proteomic strategies for individualizing therapy of acute myeloid leukemia (AML).
Curr Pharm Biotechnol. 2006 Jun;7(3):159-70. Review.
Øyan AM, Bø TH, Jonassen I, Gjertsen BT, Bruserud Ø, Kalland KH.
cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation.
Int J Oncol. 2006 May;28(5):1065-80.
Van Belle W, Anensen N, Haaland I, Bruserud Ø, Høgda KA, Gjertsen BT.
Correlation analysis of two-dimensional gel electrophoretic protein patterns and biological variables.
BMC Bioinformatics. 2006 Apr 10;7:198.
Anensen N, Skavland J, Stapnes C, Ryningen A, Børresen-Dale AL, Gjertsen BT, Bruserud Ø.
Acute myelogenous leukemia in a patient with Li-Fraumeni syndrome treated with valproic acid, theophyllamine and all-trans retinoic acid: a case report.
Leukemia. 2006 Apr;20(4):734-6. No abstract available.
Bruserud Ø, Tronstad KJ, McCormack E, Gjertsen BT.
Is targeted chemotherapy an alternative to immunotherapy in chronic lymphocytic leukemia?
Cancer Immunol Immunother. 2006 Feb;55(2):221-8. Epub 2005 Jul 21. Review.
Bruserud Ø, McCormack E, Gjertsen BT.
Immunotherapy in chronic lymphocytic leukemia.
Cancer Immunol Immunother. 2006 Feb;55(2):185-7. Epub 2005 Jul 7. Review. No abstract available.
Bruserud Ø, Stapnes C, Tronstad KJ, Ryningen A, Anensen N, Gjertsen BT.
Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML.
Expert Opin Ther Targets. 2006 Feb;10(1):51-68. Review.
Stapnes C, Ryningen A, Gjertsen BT, Bruserud Ø.
Treatment with valproic acid, all-trans retinoic acid (ATRA) and theophyllamine for 9 days caused a persistent increase in peripheral blood platelet counts for a patient with acute myelogenous leukemia.
Acta Oncol. 2006;45(3):346-9. No abstract available.
Sjøholt G, Anensen N, Wergeland L, Mc Cormack E, Bruserud Ø, Gjertsen BT.
Proteomics in acute myelogenous leukaemia (AML): methodological strategies and identification of protein targets for novel antileukaemic therapy.
Curr Drug Targets. 2005 Sep;6(6):631-46. Review.
Hatfield KJ, Olsnes AM, Gjertsen BT, Bruserud Ø.
Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies.
Curr Cancer Drug Targets. 2005 Jun;5(4):229-48. Review.
McCormack E, Bruserud O, Gjertsen BT.
Animal models of acute myelogenous leukaemia - development, application and future perspectives.
Leukemia. 2005 May;19(5):687-706. Review.
Oyan AM, Bø TH, Jonassen I, Ulvestad E, Gjertsen BT, Kalland KH, Bruserud O.
CD34 expression in native human acute myelogenous leukemia blasts: differences in CD34 membrane molecule expression are associated with different gene expression profiles.
Cytometry B Clin Cytom. 2005 Mar;64(1):18-27.
Ryningen A, Wergeland L, Glenjen N, Gjertsen BT, Bruserud O.
In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased
levels of proangiogenic Interleukin 8.
Leuk Res. 2005 Feb;29(2):185-96.
Gausdal G, Gjertsen BT, Fladmark KE, Demol H, Vandekerckhove J, Døskeland SO.
Caspase-dependent, geldanamycin-enhanced cleavage of co-chaperone p23 in leukemic apoptosis.
Leukemia. 2004 Dec;18(12):1989-96.
Dimba EA, Gjertsen BT, Bredholt T, Fossan KO, Costea DE, Francis GW, Johannessen AC, Vintermyr OK.
Khat (Catha edulis)-induced apoptosis is inhibited by antagonists of caspase-1 and -8 in human leukaemia cells.
Br J Cancer. 2004 Nov 1;91(9):1726-34.
How should clinical data be included in experimental studies of cancer immunology?
Cancer Immunol Immunother. 2004 Aug;53(8):677-80. Epub 2004 Apr 7. Review.
Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud Ø, Gjertsen BT, Nolan GP.
Single cell profiling of potentiated phospho-protein networks in cancer cells.
Cell. 2004 Jul 23;118(2):217-28.
Characterization of ribosomal P autoantibodies in relation to cell destruction and autoimmune disease.
Scand J Immunol. 2004 Jul-Aug;60(1-2):189-98.
Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients.
Blood. 2004 Apr 15;103(8):2925-8. Epub 2003 Dec 30.
Bruserud Ø, Ryningen A, Wergeland L, Glenjen NI, Gjertsen BT.
Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts.
Haematologica. 2004 Apr;89(4):391-402.
Dimba E, Gjertsen BT, Francis GW, Johannessen AC, Vintermyr OK.
Catha edulis (Khat) induces cell death by apoptosis in leukemia cell lines.
Ann N Y Acad Sci. 2003 Dec;1010:384-8.
Sandal T, Aumo L, Hedin L, Gjertsen BT, Døskeland SO.
Irod/Ian5: an inhibitor of gamma-radiation- and okadaic acid-induced apoptosis.
Mol Biol Cell. 2003 Aug;14(8):3292-304. Epub 2003 Apr 17.
Tronstad KJ, Gjertsen BT, Krakstad C, Berge K, Brustugun OT, Døskeland SO, Berge RK.
Mitochondrial-targeted fatty acid analog induces apoptosis with selective loss of mitochondrial glutathione in promyelocytic leukemia cells.
Chem Biol. 2003 Jul;10(7):609-18.
Bruserud Ø, Hovland R, Wergeland L, Huang TS, Gjertsen BT.
Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities.
Haematologica. 2003 Apr;88(4):416-28.
Hovland R, Gjertsen BT, Bruserud O.
Acute myelogenous leukemia with internal tandem duplication of the Flt3 gene appearing or altering at the time of relapse: a report of two cases.
Leuk Lymphoma. 2002 Oct;43(10):2027-9.
Bruserud Ø, Huang TS, Glenjen N, Gjertsen BT, Foss B.
Leptin in human acute myelogenous leukemia: studies of in vivo levels and in vitro effects on native functional leukemia blasts.
Haematologica. 2002 Jun;87(6):584-95.
Analysis of acute myelogenous leukemia: preparation of samples for genomic and proteomic analyses.
J Hematother Stem Cell Res. 2002 Jun;11(3):469-81. Review.
Bruserud Ø, Gjertsen BT, Ulvestad E.
Expression of Fc(epsilon)-receptors by human acute myelogenous leukemia (AML) blasts: studies of high- and low- (CD23) affinity receptor expression and the effects of IgE-mediated receptor ligation on functional AML
blast characteristics.
Leuk Res. 2002 May;26(5):515-21.
A recombinant adenovirus expressing wild-type Bax induces apoptosis in prostate cancer cells independently of their Bcl-2 status and androgen sensitivity.
Cancer Biol Ther. 2002 Mar-Apr;1(2):163-7.
Bruserud Ø, Glenjen N, Gjertsen BT, Herfindal L, Døskeland SO.
Use of marine toxins in combination with cytotoxic drugs for induction of apoptosis in acute myelogenous leukaemia cells.
Expert Opin Biol Ther. 2002 Feb;2(2):197-210. Review.
Abrahamsen JF, Bakken AM, Bruserud Ø, Gjertsen BT.
Flow cytometric measurement of apoptosis and necrosis in cryopreserved PBPC concentrates from patients with malignant diseases.
Bone Marrow Transplant. 2002 Jan;29(2):165-71.
Berentsen S, Tjønnfjord GE, Brudevold R, Gjertsen BT, Langholm R, Løkkevik E, Sørbø JH, Ulvestad E.
Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease.
Br J Haematol. 2001 Oct;115(1):79-83.
Restoration of bax in prostate cancer suppresses tumor growth and augments therapeutic cell death induction.
Anticancer Res. 2001 Sep-Oct;21(5):3141-6.
Bruserud O, Gjertsen BT, Foss B, Huang TS.
New strategies in the treatment of acute myelogenous leukemia (AML): in vitro culture of aml cells--the present use in experimental studies and the possible importance for future therapeutic approaches.
Stem Cells. 2001;19(1):1-11. Review.
Bruserud O, Gjertsen BT, von Volkman HL.
In vitro culture of human acute myelogenous leukemia (AML) cells in serum-free media: studies of native AML blasts and AML cell lines.
J Hematother Stem Cell Res. 2000 Dec;9(6):923-32.
Cimpan MR, Matre R, Cressey LI, Tysnes B, Lie SA, Gjertsen BT, Skaug N.
The effect of heat- and auto-polymerized denture base polymers on clonogenicity, apoptosis, and necrosis in fibroblasts: denture base polymers induce apoptosis and necrosis.
Acta Odontol Scand. 2000 Oct;58(5):217-28.
Bruserud O, Foss B, Abrahamsen JF, Gjertsen BT, Ernst P.
Autologous stem cell transplantation as post-remission therapy in adult acute myelogenous leukemia: does platelet contamination of peripheral blood mobilized stem cell grafts influence the risk of leukemia relapse?
J Hematother Stem Cell Res. 2000 Aug;9(4):433-43. Review.
Cimpan MR, Cressey LI, Skaug N, Halstensen A, Lie SA, Gjertsen BT, Matre R.
Patterns of cell death induced by eluates from denture base acrylic resins in U-937 human monoblastoid cells.
Eur J Oral Sci. 2000 Feb;108(1):59-69.
[The mechanism of apoptosis--therapeutic possibilities in cancer]
Tidsskr Nor Laegeforen. 2000 Jan 10;120(1):61. Norwegian. No abstract available.
Bruserud O, Gjertsen BT, Huang Ts.
Induction of differentiation and apoptosis- a possible strategy in the treatment of adult acute myelogenous leukemia.
Oncologist. 2000;5(6):454-62. Review.
Bruserud O, Tjønnfjord G, Gjertsen BT, Foss B, Ernst P.
New strategies in the treatment of acute myelogenous leukemia: mobilization and transplantation of autologous peripheral blood stem cells in adult patients.
Stem Cells. 2000;18(5):343-51. Review.
New strategies for the treatment of acute myelogenous leukemia: differentiation induction--present use and future possibilities.
Stem Cells. 2000;18(3):157-65. Review.
Fladmark KE, Brustugun OT, Hovland R, Boe R, Gjertsen BT, Zhivotovsky B, Døskeland SO.
Ultrarapid caspase-3 dependent apoptosis induction by serine/threonine phosphatase inhibitors.
Cell Death Differ. 1999 Nov;6(11):1099-108.
Bruckheimer EM, Gjertsen BT, McDonnell TJ.
Implications of cell death regulation in the pathogenesis and treatment of prostate cancer.
Semin Oncol. 1999 Aug;26(4):382-98. Review.
Jensen PH, Fladmark KE, Gjertsen BT, Vintermyr OK.
Caspase I-related protease inhibition retards the execution of okadaic acid- and camptothecin-induced apoptosis and PAI-2 cleavage, but not commitment to cell death in HL-60 cells.
Br J Cancer. 1999 Apr;79(11-12):1685-91.
Austad J, Bjerke JR, Gjertsen BT, Helland S, Livden JK, Morken T, Mørk NJ.
Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis.
J Eur Acad Dermatol Venereol. 1998 Jul;11(1):19-24.
Gjertsen BT, Logothetis CJ, McDonnell TJ.
Molecular regulation of cell death and therapeutic strategies for cell death induction in prostate carcinoma.
Cancer Metastasis Rev. 1998-1999;17(4):345-51. Review.
Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis.
Am J Hum Genet. 1997 Dec;61(6):1254-60.
Fladmark KE, Gjertsen BT, Molven A, Mellgren G, Vintermyr OK, Døskeland SO.
Gap junctions and growth control in liver regeneration and in isolated rat hepatocytes.
Hepatology. 1997 Apr;25(4):847-55.
Fladmark KE, Gjertsen BT, Døskeland SO, Vintermyr OK.
Fas/APO-1(CD95)-induced apoptosis of primary hepatocytes is inhibited by cAMP.
Biochem Biophys Res Commun. 1997 Mar 6;232(1):20-5.
Protein phosphorylation in apoptosis.
Biochim Biophys Acta. 1995 Nov 9;1269(2):187-99. Review. No abstract available.
Bøe R, Gjertsen BT, Døskeland SO, Vintermyr OK.
8-Chloro-cAMP induces apoptotic cell death in a human mammary carcinoma cell (MCF-7) line.
Br J Cancer. 1995 Nov;72(5):1151-9.
Novel (Rp)-cAMPS analogs as tools for inhibition of cAMP-kinase in cell culture. Basal cAMP-kinase activity modulates interleukin-1 beta action.
J Biol Chem. 1995 Sep 1;270(35):20599-607.
Brustugun OT, Mellgren G, Gjertsen BT, Bjerkvig R, Døskeland SO.
Sensitive and rapid detection of beta-galactosidase expression in intact cells by microinjection of fluorescent substrate.
Exp Cell Res. 1995 Aug;219(2):372-8.
Houge G, Robaye B, Eikhom TS, Golstein J, Mellgren G, Gjertsen BT, Lanotte M, Døskeland SO.
Fine mapping of 28S rRNA sites specifically cleaved in cells undergoing apoptosis.
Mol Cell Biol. 1995 Apr;15(4):2051-62.
Gjertsen BT, Cressey LI, Ruchaud S, Houge G, Lanotte M, Døskeland SO.
Multiple apoptotic death types triggered through activation of separate pathways by cAMP and inhibitors of protein phosphatases in one (IPC leukemia) cell line.
J Cell Sci. 1994 Dec;107 ( Pt 12):3363-77.
Cleaved intracellular plasminogen activator inhibitor 2 in human myeloleukaemia cells is a marker of apoptosis.
Br J Cancer. 1994 Nov;70(5):834-40.
Døskeland SO, Maronde E, Gjertsen BT.
The genetic subtypes of cAMP-dependent protein kinase--functionally different or redundant?
Biochim Biophys Acta. 1993 Sep 13;1178(3):249-58. Review. No abstract available.
Gjertsen BT, Fauske B, Døskeland SO.
Exogenous substrate stimulates autodephosphorylation of cyclic-AMP-dependent protein kinase II.
Biochem J. 1993 Sep 1;294 ( Pt 2):497-503.
Jørgensen BG, Pedersen AT, Gjertsen BT.
[Pemphigus vulgaris and benign cicatricial mucous membrane pemphigoid in the upper respiratory tract and esophagus]
Ugeskr Laeger. 1993 Jul 5;155(27):2126-9. Danish.
Vintermyr OK, Gjertsen BT, Lanotte M, Døskeland SO.
Microinjected catalytic subunit of cAMP-dependent protein kinase induces apoptosis in myeloid leukemia (IPC-81) cells.
Exp Cell Res. 1993 May;206(1):157-61.
Duprez E, Gjertsen BT, Bernard O, Lanotte M, Døskeland SO.
Antiapoptotic effect of heterozygously expressed mutant RI (Ala336-->Asp) subunit of cAMP kinase I in a rat leukemia cell line.
J Biol Chem. 1993 Apr 15;268(11):8332-40.
Bøe R, Gjertsen BT, Vintermyr OK, Houge G, Lanotte M, Døskeland SO.
The protein phosphatase inhibitor okadaic acid induces morphological changes typical of apoptosis in mammalian cells.
Exp Cell Res. 1991 Jul;195(1):237-46.
Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris.
Lancet. 1991 Jan 26;337(8735):193-6. Erratum in: Lancet 1991 Apr 20;337(8747):988.
Lanotte M, Riviere JB, Hermouet S, Houge G, Vintermyr OK, Gjertsen BT, Døskeland SO.
Programmed cell death (apoptosis) is induced rapidly and with positive cooperativity by activation of cyclic adenosine monophosphate-kinase I in a myeloid leukemia cell line.
J Cell Physiol. 1991 Jan;146(1):73-80.
Sist endret: 19.10.2012